Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Cymraeg
Cymraeg
Search
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
VPAG Programme
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Accessing medicines
›
One Wales Medicines process
›
One Wales medicine assessment documents
›
OW35 documents
OW35 documents
12/03/2026
Nivolumab plus ipilimumab for melanoma OW35 ESR
12/03/2026
Equality and Health Impact Assessment nivolumab plus ipilimumab for melanoma OW35.pdf
12/03/2026
OWMAG recommendation with starting and stopping criteria nivolumab plus ipilimumab for melanoma OW35 March 2026.pdf
12/03/2026
OWMAG decision rationale nivolumab plus ipilimumab for melanoma OW35 (redacted for website).pdf
12/03/2026
Table 5 OW35.pdf
12/03/2026
Table 4 OW35.pdf
12/03/2026
Table 3 OW35.pdf
12/03/2026
Table 2 OW35.pdf
12/03/2026
Table 1 OW35.pdf
12/03/2026
Appendix 2 OW35.pdf
12/03/2026
Appendix 4 OW35.pdf
12/03/2026
Appendix 1 OW35.pdf
12/03/2026
Appendix 3 OW35.pdf
Follow AWTTC: